Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621982 · ClinicalTrials.gov registry record · Phase 1
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT03621982 is a Phase 1 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 78 participants.
The verdict
NCT03621982, a Phase 1 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG ADCT-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621982
The ClinicalTrials.gov registry entry for NCT03621982 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03621982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03621982 about?
NCT03621982 is a clinical study titled "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors". This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
What is the current status of trial NCT03621982?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2018-11-09. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT03621982?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), ADCT-301 (DRUG).
Who is sponsoring clinical trial NCT03621982?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.